Hers vs Novi: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Novi beats Hers overall, scoring 7.8/10 vs 7.3/10. Novi is more affordable at $133/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Novi for cash-pay patients who want compounded semaglutide or tirzepa.
A side-by-side comparison of Hers and Novi covering pricing, scores, medication types, insurance, and more to help you decide.
Hers
#35 of 46The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.
Visit HersNovi
#14 of 46Telehealth platform for compounded semaglutide and tirzepatide with month-to-month billing, six named clinicians on staff, and a 3-minute pre-approval quiz. Novi emphasizes 'all-in transparent' pricing — medication, supplies, unlimited clinician check-ins, dose adjustments, and weight-loss coaching are bundled with no add-on fees. Standard pricing is $174/mo semaglutide and $283/mo tirzepatide; promotional pricing on the offer landing drops to $99-$133/mo semaglutide and $149-$166/mo tirzepatide with $200 off advertised.
Visit Novi| Feature | Hers | Novi |
|---|---|---|
| Our Score | 7.3/10 | 7.8/10 |
| Starting Price | $199/mo | $133/mo |
| Medication Type | Both | Compounded |
| Insurance Accepted | No | No |
| Best For | Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand | Cash-pay patients who want compounded semaglutide or tirzepatide on a no-commitment plan with named clinicians, unlimited check-ins, and aggressive promotional pricing as low as $99-$133/mo on the introductory offer |
| Ranking | #35 | #14 |
Pros & Cons Compared
Hers
Pros
- +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services
Cons
- −Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
- −Generic support experience — large patient volume means less personalized attention
- −Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
- −Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value
Novi
Pros
- +Six disclosed clinicians on staff — Daniel Funsch MD, Michael Wasef MD, Takashi Nakamura MD plus three nurse practitioners (Hastings NP, Clements NP, Vergara DNP) — more named providers than most compounded-only platforms publish
- +Month-to-month billing with no minimum commitment — cancel before any renewal date with no early-termination penalty
- +Aggressive promotional pricing on the offer landing — $99-$133/mo compounded semaglutide and $149-$166/mo compounded tirzepatide with a $200 OFF intro discount
- +Unlimited clinician check-ins, dose adjustments, and weight-loss coaching included at no additional cost
- +Free 2-day shipping; same active ingredients as Wegovy/Ozempic and Mounjaro/Zepbound (semaglutide and tirzepatide respectively)
- +100,000+ patients claimed and editorial coverage in Bloomberg, Forbes, and WebMD provide third-party signal
Cons
- −Compounded-only — no FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro through the platform; no Foundayo or oral GLP-1 formats
- −Founding year, headquarters city, and corporate ownership are not publicly disclosed
- −Promotional $99-$133 pricing applies to the introductory offer landing only — standard rate after any qualifying intro period is $174-$283/mo (verify the renewal rate before enrolling)
- −Once medication is dispensed/shipped, prescriptions cannot be returned or refunded — typical for compounded telehealth but worth understanding
- −Lab requirements before prescribing are not disclosed on public pages — unclear whether baseline bloodwork is required
- −Multiple landing pages (offer-v4, offer-v6-low) show different headline prices, which can create pricing confusion before checkout
Our Verdict
Novi edges out Hers with a score of 7.8/10 vs 7.3/10. If budget is your priority, Novi starts at $133/mo compared to Hers's $199/mo. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Novi if you want: cash-pay patients who want compounded semaglutide or tirzepatide on a no-commitment plan with named clinicians, unlimited check-ins, and aggressive promotional pricing as low as $99-$133/mo on the introductory offer.